-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IJHzNfLLXth8T+ioU7Vt3f1FL0UZL/p4eNgV7Nac6uNyhy25I450oVa2/ys9MKMP qkHrMurHs7k+6pRw5Pvwug== 0001005794-10-000125.txt : 20100830 0001005794-10-000125.hdr.sgml : 20100830 20100712154608 ACCESSION NUMBER: 0001005794-10-000125 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20100712 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROVECTUS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000315545 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900031917 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 7327 OAK RIDGE HWY STREET 2: SUITE B CITY: KNOXVILLE STATE: TN ZIP: 37931 BUSINESS PHONE: 865-769-4011 MAIL ADDRESS: STREET 1: 7327 OAK RIDGE HWY STREET 2: SUITE B CITY: KNOXVILLE STATE: TN ZIP: 37931 FORMER COMPANY: FORMER CONFORMED NAME: ZAMAGE DIGITAL IMAGING INC DATE OF NAME CHANGE: 20011126 FORMER COMPANY: FORMER CONFORMED NAME: SPM GROUP INC DATE OF NAME CHANGE: 19920703 CORRESP 1 filename1.htm pvctcorrespondence071210b.htm
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Highway, Suite A
Knoxville, Tennessee 37931

VIA EDGAR AND FACSIMILE

United States Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Attn: Jeffrey P. Riedler, Assistant Director

Re:          Provectus Pharmaceuticals, Inc.
Registration Statement on Form S-3
File June 30, 2010
File No. 333-167906

Dear Mr. Riedler:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the "Securities Act"), Provectus Pharmaceuticals, Inc. (the "Company") hereby requests acceleration of the effectiveness of the Company's Registration Statement on Form S-3/A, file number 333-167906, for July 14, 2010 at 9:00 a.m. Eastern Time, or as soon as practicable thereafter.

This letter will confirm that the Company acknowledges that:

·  
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

·  
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

·  
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

          Very truly yours,
 
          PROVECTUS PHARMACEUTICALS, INC.
 
          By: /s/Peter R. Culpepper                                  
          Name: Peter R. Culpepper
          Title: Chief Financial Officer and Chief Operating Officer
 

 

 
 
 

-----END PRIVACY-ENHANCED MESSAGE-----